Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4278028 | 0.89 | PTGER3 (0.45) | KDM4EPTGER3NPC1RAB9AAPOBEC3A | |
| SCHEMBL18593244 | 0.89 | PTGER3 (0.55) | KDM4EPTGER3NPC1RAB9AAPOBEC3A | |
| SCHEMBL29976743 | 0.81 | MEN1 (0.56) | KDM4EPTGER3KMT2AMEN1HPGD | |
| SCHEMBL13596347 | 0.81 | MEN1 (0.56) | KDM4EPTGER3KMT2AMEN1HPGD | |
| SCHEMBL20116560 | 0.81 | NOS3 (0.42) | PTGER3NPC1RAB9AAPOBEC3AAPOBEC3G | |
| SCHEMBL20660979 | 0.81 | NOS3 (0.42) | PTGER3NPC1RAB9AAPOBEC3AAPOBEC3G | |
| SCHEMBL20660975 | 0.80 | PTGER3 (0.41) | PTGER3NPC1RAB9AAPOBEC3AAPOBEC3G | |
| SCHEMBL13180252 | 0.77 | NR3C1 (0.42) | PTGER3KMT2ANR3C1PGRAR | |
| SCHEMBL24826392 | 0.76 | NR3C1 (0.44) | PTGER3HPGDNR3C1PGRAR | |
| SCHEMBL5516550 | 0.76 | NR3C1 (0.41) | KDM4EPTGER3KMT2AMEN1NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10029995-B2 | [6,6] fused bicyclic HDAC8 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170066729-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | Valo Health, LLC | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066729-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | KDM4E 192/4885PTGER3 2832/4885NPC1 2435/4885 |
| US-10029995-B2 | [6,6] fused bicyclic HDAC8 inhibitors | HDAC8, HDAC3, HDAC2 | KDM4E 192/4885PTGER3 2832/4885NPC1 2435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.